Drug industry trade group Pharmaceutical Research and Manufacturers of America and drug manufacturer Bristol Myers Squibb have filed separate federal lawsuits to stop Medicare from negotiating the prices of some drugs, charging that it would impose unconstitutional price controls on
…
The Medicare Payment Advisory Commission is sticking by its long-standing recommendation that Medicare should pay less for Part B drugs furnished by 340B hospitals.
“We continue to believe that this approach is appropriate, and the specific level of payment reduction
…
The U.S. Chamber of Commerce and three state and local affiliates are asking a federal court to strike down the part of the Inflation Reduction Act that lets Medicare negotiate “maximum fair prices” (MFPs) for some expensive, single-source drugs, arguing
…
Nonprofit hospitals’ profits and cash reserves grew substantially between 2012 and 2019 without a corresponding rise in spending on charity care, a new study in the June issue of Health Affairs found.
The American Hospital Association quickly issued a rebuttal.
…
Rural hospitals that enroll in the 340B drug pricing program are more likely to initiate oncology services than those that do not participate, a study published online Monday in Health Affairs found.
“It’s estimated that around one in five rural
…
New York State is appealing a state trial court’s dismissal of its antitrust case against CVS Health that alleges the pharmacy giant unlawfully forces 340B covered entities to use its 340B third party administrator Wellpartner in order to contract with
…
Companion bills in the Massachusetts House and Senate would restore the 340B program’s intent by stopping pharmacy benefit manager discrimination against any 340B covered entities and their contract pharmacies, the sponsor of the state Senate bill said during a recent
…
340B-eligible providers prescribe generic drugs at the same overall rate as non-340B providers, a study published in JAMA Health Forum found. “We found no evidence that 340B-eligible prescribers were systematically overprescribing brand-name drugs to generate revenue,” the authors said.
Arkansas’ 340B contract pharmacy law, for now the only state law of its kind, has no place in the federal 340B “closed system,” Pharmaceutical Research and Manufacturers of America (PhRMA) recently told a federal appeals court.
“340B is a closed
…*Sign up for news summaries and alerts from 340B Report